BBBraden Burdekin

Braden Burdekin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Braden Burdekin has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Mary-Keara Boss

    Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences Colorado State University Fort Collins Colorado USA

    3 shared publications
  • Ber-In Lee

    Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University

    2 shared publications
  • Emily D. Rout

    Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA

    2 shared publications
  • Erin Trageser

    Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University

    2 shared publications
  • Lauren Harrison

    Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University

    2 shared publications
  • Madison Rivera

    Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University

    2 shared publications

Latest Publications

  • JoVE Video Dataset

    by Mary-Keara Boss, Braden Burdekin, Lauren Harrison, Madison Rivera, Adam Harris, Emily Rout, Erin Trageser, Patricia Gualtieri, Ber-In Lee, Steven Dow

    Evaluating the local immune microenvironment of the canine nasal cavity can be important for investigating normal tissue health and disease conditions, particularly those associated with local inflammation. We have optimized a technique to evaluate the local nasal immune microenvironment of dogs via serial nasal lavage. Briefly, with dogs under anesthesia and positioned in sternal recumbency, prewarmed sterile saline is flushed into the affected nostril using a flexible soft rubber catheter. The fluid backflow is collected into conical tubes, and this process is repeated. The fluids containing dislodged cells and proteins are pooled, and the pooled nasal lavage samples are filtered through a cell strainer to remove large debris and mucus. Samples are centrifuged and the cell pellets are isolated for analysis. Once the samples have been processed, analyses that may follow nasal lavage include flow cytometry, transcriptomic analysis of cells via bulk or single-cell RNA seq, and/or quantification of cytokines present in the lavage fluid.

  • Saline Lavage for Sampling of the Canine Nasal Immune Microenvironment

    by Mary-Keara Boss, Braden Burdekin, Lauren Harrison, Madison Rivera, Adam Harris, Emily Rout, Erin Trageser, Patricia Gualtieri, Ber-In Lee, Steven Dow

    Evaluating the local immune microenvironment of the canine nasal cavity can be important for investigating normal tissue health and disease conditions, particularly those associated with local inflammation. We have optimized a technique to evaluate the local nasal immune microenvironment of dogs via serial nasal lavage. Briefly, with dogs under anesthesia and positioned in sternal recumbency, prewarmed sterile saline is flushed into the affected nostril using a flexible soft rubber catheter. The fluid backflow is collected into conical tubes, and this process is repeated. The fluids containing dislodged cells and proteins are pooled, and the pooled nasal lavage samples are filtered through a cell strainer to remove large debris and mucus. Samples are centrifuged and the cell pellets are isolated for analysis. Once the samples have been processed, analyses that may follow nasal lavage include flow cytometry, transcriptomic analysis of cells via bulk or single-cell RNA seq, and/or quantification of cytokines present in the lavage fluid.


  • Open Access

    Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model

    by Amber R. Prebble, Bailey Latka, Braden Burdekin, Del Leary, Mac Harris, Daniel Regan, Mary-Keara Boss

    Tyrosine kinase inhibitors (TKIs) may be combined with radiation therapy (RT) to enhance tumor control; however, increased incidences of gastrointestinal (GI) toxicity have been reported with this combination. We hypothesize that toxicity is due to compromised intestinal healing caused by inhibition of vascular repair and proliferation pathways. This study explores underlying tissue toxicity associated with abdominal RT and concurrent sunitinib in a mouse model. Four groups of CD-1 mice were treated with 12 Gy abdominal RT, oral sunitinib, abdominal RT + sunitinib, or sham treatment. Mice received oral sunitinib or the vehicle via gavage for 14 days. On day 7, mice were irradiated with 12 Gy abdominal RT or sham treated. Mice were euthanized on day 14 and intestinal tract was harvested for semiquantitative histopathologic evaluation and immunohistochemical quantification of proliferation (Ki67) and vascular density (CD31). Non-irradiated groups had stable weights while abdominal irradiation resulted in weight loss, with mice receiving RT + SUN having greater weight loss than mice receiving RT alone. Semiquantitative analysis showed significant increases in inflammation in irradiated groups. The difference in the density of CD31+ cells was significantly increased in RT alone compared to SUN alone. Ki67+ density was not significant. In summary, we identify a lack of angiogenic response in irradiated GI tissues when abdominal RT is combined with a TKI, which may correlate with clinical toxicities seen in canine and human patients receiving combined treatment.